Market closed
Aeglea BioTherapeutics, Inc./$SYRE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Aeglea BioTherapeutics, Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
Ticker
$SYRE
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
65
Website
SYRE Metrics
BasicAdvanced
$764M
-
-$3.18
2.99
-
Price and volume
Market cap
$764M
Beta
2.99
52-week high
$21.03
52-week low
$10.91
Average daily volume
794K
Financial strength
Current ratio
11.256
Quick ratio
11.156
Management effectiveness
Return on assets (TTM)
-27.43%
Return on equity (TTM)
-59.28%
Valuation
Price to book
2.11
Price to tangible book (TTM)
2.11
Price to free cash flow (TTM)
-3.785
Growth
Earnings per share change (TTM)
-76.88%
3-year earnings per share growth (CAGR)
-49.72%
SYRE News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Aeglea BioTherapeutics, Inc. stock?
Aeglea BioTherapeutics, Inc. (SYRE) has a market cap of $764M as of April 19, 2025.
What is the P/E ratio for Aeglea BioTherapeutics, Inc. stock?
The price to earnings (P/E) ratio for Aeglea BioTherapeutics, Inc. (SYRE) stock is 0 as of April 19, 2025.
Does Aeglea BioTherapeutics, Inc. stock pay dividends?
No, Aeglea BioTherapeutics, Inc. (SYRE) stock does not pay dividends to its shareholders as of April 19, 2025.
When is the next Aeglea BioTherapeutics, Inc. dividend payment date?
Aeglea BioTherapeutics, Inc. (SYRE) stock does not pay dividends to its shareholders.
What is the beta indicator for Aeglea BioTherapeutics, Inc.?
Aeglea BioTherapeutics, Inc. (SYRE) has a beta rating of 2.99. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.